Please note, this OEL/ADE monograph also applies to vinblastine sulfate (CAS RN 143-67-9). Vinblastine sulfate injection is indicated in the palliative treatment of the following frequently responsive malignancies - Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system), lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated), histiocytic lymphoma, mycosis fungoides (advanced stages), advanced carcinoma of the testis, Kaposi’s sarcoma, Letterer-Siwe disease (histiocytosis X) and the following less frequently responsive malignancies - Choriocarcinoma resistant to other chemotherapeutic agents and carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Vinblastine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.